疫苗衍生脊髓灰质炎病毒相关病例的研究进展

陈明文 李文

陈明文, 李文. 疫苗衍生脊髓灰质炎病毒相关病例的研究进展[J]. 疾病监测, 2014, 29(3): 243-246. doi: 10.3784/j.issn.1003-9961.2014.03.020
引用本文: 陈明文, 李文. 疫苗衍生脊髓灰质炎病毒相关病例的研究进展[J]. 疾病监测, 2014, 29(3): 243-246. doi: 10.3784/j.issn.1003-9961.2014.03.020
CHEN Ming-wen, LI Wen. Progress in research on vaccine derived polio virus related polio case[J]. Disease Surveillance, 2014, 29(3): 243-246. doi: 10.3784/j.issn.1003-9961.2014.03.020
Citation: CHEN Ming-wen, LI Wen. Progress in research on vaccine derived polio virus related polio case[J]. Disease Surveillance, 2014, 29(3): 243-246. doi: 10.3784/j.issn.1003-9961.2014.03.020

疫苗衍生脊髓灰质炎病毒相关病例的研究进展

doi: 10.3784/j.issn.1003-9961.2014.03.020

Progress in research on vaccine derived polio virus related polio case

  • 摘要: 目的 了解脊髓灰质炎(脊灰)疫苗衍生病毒 (VDPV)的发生情况和影响因素,探讨降低VDVP发生的有效措施。方法 对口服脊灰减毒活疫苗(OPV)引发的VDVP的分类、发生情况,病毒型别分布,人群分布,OPV免疫剂次与VDVP发生的关系进行综述。结果 全球已报告多起疫苗相关性脊灰事件,病毒型别主要为Ⅱ型,其次为Ⅰ型。VDVP的发生主要与疫苗株病毒的基因突变、重组有关。机体免疫缺陷者更易发生。结论 在消灭脊灰的后期,消除VDVP将成为消灭脊灰的重要工作内容,为此,有关学者建议停止使用OPV,改用脊灰灭活疫苗或两种疫苗相结合的序贯免疫程序。
  • [1] CentersforDiseaseControlandPrevention.Laboratorysurveillanceforwildandvaccine-derivedpolio-viruses-worldwide,January2006-June2007[J].MMWR,2007,56(37):965-969.
    [2] KewOM,SutterRW,deGourvilleEM,etal.Vaccine-derivedpoliovirusesandtheendgamestrategyforglobalpolioeradication[J].AnnuRevMicrobiol,2005,59:587-635.
    [3] NathansonN,KewOM.Fromemergencetoeradication:theepidemiologyofpoliomyelitisdeconstructed[J].AmJEpidemiol,2010,172(11):1213-1229.
    [4] ZhangY,YanDM,ZhaoR,etal.Predominantgeneticcharacteristicofvaccine-derivedpoliovirusstrainsisolatedfromacuteflaccidparalysiscasesanditscausesinChina[J].ChineseJournalofVaccinesandImmunization,2006,12(3):371-378.(inChinese)张勇,严冬梅,赵蓉,等.中国急性弛缓性麻痹病例脊髓灰质炎疫苗病毒分离株中优势的基因特征及形成原因浅析[J].中国计划免疫,2006,12(3):371-378.
    [5] UpdateC.Outbreakofpoliomyelitis-DominicanRepublicandHaiti,2000-2001[J].MMWR,2001,50(39):855-856.
    [6] ShimizuH,ThorleyB,PaladinFJ,etal.Circulationoftype1vaccine-derivedpoliovirusinthePhilippinesin2001[J].JViro,2004,78(24):13512-13521.
    [7] RoussetD,Rakoto-AndrianariveloM,RazafindratsimandresyR,etal.Recombinantvaccine-derivedpoliovirusinMadagascar[J].EmergInfectDis,2003,9(7):885-887.
    [8] liangX,ZhangY,XuW,etal.Anoutbreakofpoliomyelitiscausedbytype1vaccine-derivedpoliovirusinChina[J].JInfectDis,2006,194(5):545-551.
    [9] YanD,LiL,ZhuS,etal,Emergenceandlocalizedcirculationofavaccine-derivedpoliovirusinanisolatedmountaincommunityinGuangxi,China[J].JClinlMicrobiol,2010,48(9):3274-3280.
    [10] ShahmahmoodiS,MamishiS,aghamohammadiA,etal.Vaccineassociatedparalyticpoliomyelitisinimmunodeficientchildren,Iran,1995-2008[J].EmergInfectDis,2010,16(7):1133-1136.
    [11] WassilakS,PateMA,Wanne.muehlerK,etal.Outbreakoftype2vaccine-derivedpoliovirusinNigeria:emergenceandwidespreadcirculationinanunderimmunizedpopulation[J].JInfectDis,2011,203(7):898-909.
    [12] AvellonA,CabrerizoM,DEMiguelT,etal.Parakysiscaseandcontactspreadofrecombinantvaccinederivedpoliovirusspain[J].EmergInfecDis,2008,14(11):1807-1809.
    [13] CentersforDiseaseControlandPrevention.Updateonvaccine-derivedpoliovirus[J].MMWR,2006,55(40):1093-1097.
    [14] LiuDQ,LiL,WangBB,etal.Epidemiologyofthefirstvaccine-derivedpoliovirusinfectioninimmunodeficiencypersonandcontrolmeasuresinChina[J].ChineseJournalofVaccinesandImmunization,2006,12(6):459-463.(inChinese)刘丹青,李黎,王斌冰,等.中国首例免疫缺陷疫苗衍生脊髓灰质炎病毒病例的流行病学分析及其控制对策[J].中国计划免疫,2006,12(6):459-463.
    [15] LiL,XuAQ,LiRP,etal.Progressinresearchofvaccine-derivedpoliovirus[J].ChineseJournalofVaccinesandImmunization,2007,13(6):595-599.(inChinese)李黎,徐爱强,李仁鹏,等.疫苗衍生脊髓灰质炎病毒相关研究进展[J].中国计划免疫,2007,13(6):595-599.
    [16] GuFZ.Poliomyelitis[M]//Sabin.Shanghai:ShanghaiScienceandTechnologyPress,1984.(inChinese)顾方舟.脊髓灰质炎[M].//Sabin.上海:上海科技出版社,1984.
    [17] MacadamAI,PollardSR,FergusonG,etal.The5'noncodingregionofthetype2poliovirusvaccinestraincontainsdeterminantsofattenuationandtemperaturesensitivity[J].Virology,1991,181(2):451-458.
    [18] AritaM,zhuSL,YoshidaH,etal.ASabin3-derivedpoliovirusrecombinantcontainedasequencehomologouswithindigenoushumanenterovirusspeciesCintheviralpolymerasecodingregion[J].JVirol,2005,79(20):12650-12657.
    [19] ZhangLB,YeXF.Circulationandpathogenicityofrecombinantvaccine-derivedpoliovirusstrainsinChina[J].ChineseJournalofVaccinesandImmunization,2001,7(3):125-128.(inChinese)张礼璧,叶绪芳.脊髓灰质炎疫苗重组株病毒在我国的循环及其致病性[J].中国计划免疫,2001,7(3):125-128.
    [20] ZhangY,ZhuS,YanD,etal.Naturaltype3/type2intertypicvaccine-relatedpoliovirusrecombinantswiththefirstcrossoversiteswithintheVPIcapsidcodingregion[J].PLoSOne,2010,5(12):e15300.
    [21] deSilvaR,GunasenaS,RatnayakeD,etal.PrevalenceofprolongedandchronicpoliovirusexcretionamongpersonswithprimaryimmunedeficiencydisordersinSriLanka[J].Vaccine,2012,30(52):7561-7565.
    [22] AlexanderJrJP,GaryJrHE,PallanschMA.Durationofpoliovirusexcretionanditsimplicationsforacuteflaccidparalysissurverillance:areviewoftheliterature[J].JInfecDis,1997,175:S176-182.
    [23] ChitsikeI,vanFurthR.ParalyticpoliomyelitisassociatedwithliveoralpoliomyelitisvaccineinchildwithHIVinfectioninZIMbabwe:casereport[J].BMJ,1999,318(7187):841-843.
    [24] PrevotsDR,StrebelPM.PoliomyelitispreventionintheUnitedStates:newrecommendationsforroutinechildhoodvaccinationplacegreaterrelianceoninactivatedpoliovirusvaccine[J].PediatrAnn,1997,26(6):378-383.
    [25] AlexanderLN,SewardJF,SantibanezTA,etal.VaccinepolicychangesandepidemiologyofpoliomyelitisintheUnitedStates[J].JAMA,2004,292(14):1696-1701.
    [26] KnolleH,EgliA,CandrianU.Theperspectiveofglobaleradicationofpoliomyelitis[J].Gesundheitswesen,2004,66(1):1-6.
    [27] CDC.PoliomyelitisPreventionintheunitedstates[J].MMWR,2000,49(RR-5):7-14.
  • 加载中
计量
  • 文章访问数:  838
  • HTML全文浏览量:  19
  • PDF下载量:  234
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-10-08
  • 刊出日期:  2014-03-20

目录

    /

    返回文章
    返回

    在线交流

    防诈骗公告

    近期有不法分子以本刊编辑身份添加作者微信,请务必提高警惕!本刊关于稿件的一切事项通知均采用编辑部唯一邮箱(jbjc@icdc.cn)和座机(010-58900732)联系作者,且在录用稿件后仅收取版面费,无其他任何名目费用(如审稿费和加急费等),非编辑部邮箱发送的本刊收费用通知等均为诈骗,不要随意汇入款项!如有可疑及时致电编辑部核实确认!